Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.
作者信息
Moyana Terence, Merz Valeria
机构信息
Diagnostic & Molecular Pathology, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy.
出版信息
Front Oncol. 2025 Jul 8;15:1651566. doi: 10.3389/fonc.2025.1651566. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.
Front Oncol. 2025 Jul 8;15:1651566. doi: 10.3389/fonc.2025.1651566. eCollection 2025.
2
Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma-a systematic review and meta-analysis.
Transl Res. 2022 Jun;244:126-136. doi: 10.1016/j.trsl.2022.01.001. Epub 2022 Jan 20.
3
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.
J Pers Med. 2025 Jun 5;15(6):236. doi: 10.3390/jpm15060236.
4
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):634-647. doi: 10.1016/S2468-1253(25)00056-1. Epub 2025 May 16.
5
Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.
J Cancer Res Clin Oncol. 2023 Jun;149(6):2279-2292. doi: 10.1007/s00432-022-04315-4. Epub 2022 Sep 6.
6
Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment.
Medicina (Kaunas). 2025 Jun 11;61(6):1076. doi: 10.3390/medicina61061076.
7
Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy.
Nanotheranostics. 2025 Jun 12;9(2):171-185. doi: 10.7150/ntno.110074. eCollection 2025.
8
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
9
The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
J Cancer Res Clin Oncol. 2018 Dec;144(12):2419-2431. doi: 10.1007/s00432-018-2755-9. Epub 2018 Sep 22.
10
Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28.
本文引用的文献
1
Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications.
Int J Mol Sci. 2025 Feb 12;26(4):1562. doi: 10.3390/ijms26041562.
2
Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS protein to cancer-associated fibroblasts.
Mol Ther. 2025 Mar 5;33(3):1134-1153. doi: 10.1016/j.ymthe.2025.01.023. Epub 2025 Jan 14.
3
Prognostic Value of Residual Circulating Tumor DNA in Metastatic Pancreatic Ductal Adenocarcinoma.
Ann Lab Med. 2025 Mar 1;45(2):199-208. doi: 10.3343/alm.2024.0345. Epub 2025 Jan 13.
4
Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer.
Cell Oncol (Dordr). 2025 Apr;48(2):269-293. doi: 10.1007/s13402-024-00990-2. Epub 2024 Sep 19.
5
FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.
NPJ Precis Oncol. 2024 Sep 17;8(1):207. doi: 10.1038/s41698-024-00683-x.
6
Molecular insights to therapeutic in cancer: role of exosomes in tumor microenvironment, metastatic progression and drug resistance.
Drug Discov Today. 2024 Aug;29(8):104061. doi: 10.1016/j.drudis.2024.104061. Epub 2024 Jun 18.
7
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
8
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
9
CA19-9 and CEA biosensors in pancreatic cancer.
Clin Chim Acta. 2024 Feb 1;554:117788. doi: 10.1016/j.cca.2024.117788. Epub 2024 Jan 20.
10
Pancreatic ductal adenocarcinoma staging: a narrative review of radiologic techniques and advances.
Int J Surg. 2024 Oct 1;110(10):6052-6063. doi: 10.1097/JS9.0000000000000899.
Zotero 插件